Eikon Therapeutics, Inc., is a clinical biopharmaceutical company in the United States. The company is headquartered in Millbrae, California.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-310.08M |
| Operating Margin | 0.00% |
| Return on Equity | -125.00% |
| Return on Assets | -36.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $10.17 |
| Price-to-Book | 1.23 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $54.14M |
| Float | $29.84M |
| % Insiders | 17.39% |
| % Institutions | 64.52% |
Volatility is currently expanding
Addition reflects Eikon's progress as a publicly traded company and increasing visibility within the investment community Addition reflects Eikon's progress as a publicly traded company and increasing visibility within the investment community
Eikon Therapeutics is initiated with a cautious buy, leveraging industry-leading management and a robust oncology-focused pipeline. EIKN's ASCO data for EIK1001 in NSCLC showed a 63.1% ORR and favorable safety, but the market response was muted. Cash reserves of $596m provide a runway into 2027 despite high R&D burn; valuation is now below cash, reflecting skepticism.
MILLBRAE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today reported first quarter 2026 financial results and provided updates on its lead clinical programs.
